[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523193":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":36,"responsibleParty":72,"collaborators":11,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":11,"enrollmentInfo":84,"targetDuration":11,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Zuyderland Medisch Centrum","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tailored, Urine sodium guided, intensified diuretic strategy","EXPERIMENTAL",null,[13],"Other: Urine sodium guided diuretic algorithm",{"label":15,"type":16,"description":11,"interventionNames":17},"Usual care","ACTIVE_COMPARATOR",[18],"Other: Usual care",[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"Urine sodium guided diuretic algorithm","Loop diuretics are administered intravenously as soon as possible after diagnosis of ADHF and continued 3dd until recompensation. Spot urine sodium is measured 2 hours after administration of the first in-hospital IV diuretic dose and repeated until the target of 100mmol\u002FL is reached in the first 72 hours of admission (after which, UrNa will be measured once daily). When target is not met, the next dosage of loop diuretic is doubled (max 3dd 250mg furosemide) and thereafter, other diuretics (thiazide, MRA) are added. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.",[9],{"type":6,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Treatment with IV loop diuretics left to the discretion of the treating physician. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.",[15],[28,33],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Sandra van Wijk, MD, PhD","CONTACT","088 - 459 9701","s.vanwijk@zuyderland.nl",{"name":34,"role":30,"phone":31,"phoneExt":11,"email":35},"Mick Hoen, MD","m.hoen@zuyderland.nl",[37,54],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Zuyderland MC","RECRUITING","Heerlen","Limburg","6419 PC","Netherlands","NL",{"type":46,"coordinates":47},"Point",[48,49],5.98154,50.88365,{"lat":49,"lon":48},[52,53],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":11},{"name":34,"role":30,"phone":31,"phoneExt":11,"email":11},{"facility":55,"status":39,"city":56,"state":57,"zip":58,"country":43,"countryCode":44,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Amphia ziekenhuis","Breda","North Brabant","4818 CK",{"type":46,"coordinates":60},[61,62],4.77596,51.58656,{"lat":62,"lon":61},[65,69],{"name":66,"role":30,"phone":67,"phoneExt":11,"email":68},"Ijsbrand dr. Klip, MD, PhD","+31765953018","RDCardio@amphia.nl",{"name":70,"role":71,"phone":11,"phoneExt":11,"email":11},"Ijsbrand Dr. Klip, MD, PhD","PRINCIPAL_INVESTIGATOR",{"type":73,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100523193","investigating-a-tailored-diuretic-algorithm-in-acute-heart-failure-patients-100523193",false,"NCT06092437","Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients","TAILOR-AHF: Randomized Trial Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients","TAILOR-AHF","Inclusion Criteria:\n\n* Age \\> 18 years;\n* HF (HFrEF, HFmrEF or HFpEF) diagnosed according to the 2021 HF Guidelines of the European Society of Cardiology \\[5\\];\n* Presentation with AHF meaning at least one symptom (dyspnea, orthopnea, or edema) and one sign (rales, peripheral edema, ascites, or pulmonary vascular congestion on chest radiography) of AHF;\n* An elevated NT-proBNP \\>300pg\u002Fml;\n* Requiring the need for iv diuretics.\n\nExclusion Criteria:\n\n* Terminal renal insufficiency defined as: dialysis patients or eGFR (estimated glomerular filtration rate) \\\u003C 10 mL\u002Fmin\u002F1.73 m2;\n* Patients included in other investigational studies regarding heart failure.\n* Presentation with cardiogenic shock or respiratory insufficiency or another reason requiring admission to the intensive care unit upon admission (IC transfer later in the hospitalization is not an exclusion).","ALL","18 Years",{"count":85,"type":86},556,"ESTIMATED","INTERVENTIONAL",[89],"NA","Acutely decompensated heart failure (ADHF) is highly prevalent and has a high (financial) burden on the health care system. Treatment often consists of the administration of IV decongestive agents. Adequate dosing is difficult due to varying diuretic resistance and inadequate parameters to evaluate the response. Urine sodium is a promising biomarker to evaluate the diuretic response. It is hypothesized that a tailored, urine sodium guided diuretic algorithm will result in faster and more complete decongestion and therefore lead to better survival (in terms of mortality and heart failure events) while being non-inferior in terms of safety (mainly regression of kidney function).",[92],"Heart Failure Acute",[94,95,96,97],"Decongestion","Heart failure","Natriuresis","Urinary Sodium","2026-04-07",{"date":100,"type":101},"2026-04-13","ACTUAL",{"date":103,"type":101},"2023-02-27",{"date":105,"type":86},"2026-08-27",{"name":5,"class":6},2]